OBJECTIVES: Matrix metalloproteinase (MMP)-1 degrades fibrillar collagens suggesting important role in vascular remodeling. Data about MMP-1 promoter polymorphisms and carotid atherosclerosis (CA) are scarce. The aim of this study was to evaluate association of MMP-1 genotypes/haplotypes with carotid plaque (CP) presence in Serbian population. DESIGN AND METHODS: Study enrolled a total of 702 participants: 274 controls and 428 consecutive patients with CA who underwent carotid endarterectomy. MMP-1 polymorphisms -1607 1G/2G, -519 A/G and -340 T/C were genotyped by PCR and RFLP methods. RESULTS: Individuals carrying MMP-1 -1607 2G allele had significantly increased allele dose-dependent risk for CP presence (1G1G vs. 1G2G vs. 2G2G; OR=1; OR=1.87 95% CI 1.29-2.07; OR=3.49 95% CI 1.67-7.30, p=0.0009, respectively). Compared to the referent haplotype 2G(-1607)-T(-340)-A(-519), the haplotypes 1G(-1607)-T(-340)-A(-519), 1G(-1607)-T(-340)-G(-519) and 2G(-1607)-C(-340)-A(-519) had statistically significant protective effect on CP presence (OR=0.41, 95% CI 0.29-0.81, p=0.01; OR=0.56, 95% CI 0.44-0.89, p=0.01; OR=0.43, 95% CI 0.27-0.86, p=0.02, respectively). CONCLUSIONS: MMP-1 -1607 G/2G polymorphism solely and specific haplotypes of three analyzed promoter polymorphisms are significantly and independently associated with occurrence of CP. Replication studies in other populations are needed.
OBJECTIVES:Matrix metalloproteinase (MMP)-1 degrades fibrillar collagens suggesting important role in vascular remodeling. Data about MMP-1 promoter polymorphisms and carotid atherosclerosis (CA) are scarce. The aim of this study was to evaluate association of MMP-1 genotypes/haplotypes with carotid plaque (CP) presence in Serbian population. DESIGN AND METHODS: Study enrolled a total of 702 participants: 274 controls and 428 consecutive patients with CA who underwent carotid endarterectomy. MMP-1 polymorphisms -1607 1G/2G, -519 A/G and -340 T/C were genotyped by PCR and RFLP methods. RESULTS: Individuals carrying MMP-1 -1607 2G allele had significantly increased allele dose-dependent risk for CP presence (1G1G vs. 1G2G vs. 2G2G; OR=1; OR=1.87 95% CI 1.29-2.07; OR=3.49 95% CI 1.67-7.30, p=0.0009, respectively). Compared to the referent haplotype 2G(-1607)-T(-340)-A(-519), the haplotypes 1G(-1607)-T(-340)-A(-519), 1G(-1607)-T(-340)-G(-519) and 2G(-1607)-C(-340)-A(-519) had statistically significant protective effect on CP presence (OR=0.41, 95% CI 0.29-0.81, p=0.01; OR=0.56, 95% CI 0.44-0.89, p=0.01; OR=0.43, 95% CI 0.27-0.86, p=0.02, respectively). CONCLUSIONS:MMP-1 -1607 G/2G polymorphism solely and specific haplotypes of three analyzed promoter polymorphisms are significantly and independently associated with occurrence of CP. Replication studies in other populations are needed.